Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Surge In Applications Triggers User Fee Inflation

Executive Summary

With full NDA and BLA submissions to FDA now growing faster than INDs and supplements, user fees are increasing more rapidly as well.

Advertisement

Related Content

What Goes Up … US FDA Expects 2016 NME Approval Total To Come Down
PDUFA Fees Forced Down For FY 2017 Due To Refund Provision
Will PDUFA VI Fee Structure Changes Slow Revenue Growth?
FDA Personnel Growth Looks To Have Plateaued For Drugs Program
FDA’s Rent Is Too Damn High: Consolidated Labs Cost More Than Off-Campus Space
‘Breakthrough’ Drugs Get ‘Road-MaPP’ – Complete With Communication Timetable
Drug Shortages Mostly FDA’s Fault, House Oversight Committee Concludes

Topics

Advertisement
UsernamePublicRestriction

Register

PS057063

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel